Pluristem to present PLX-PAD cell data later this month

Pluristem Therapeutics (PSTI +4.7%) gets an early lift from an announcement that the company will present results of a Phase 1/2 clinical trial of PLX-PAD cells for the treatment of muscle injury on January 21.

"Data from this clinical trial will give us information regarding other potential surgical orthopedic injuries and non-surgical sports related injuries for which our PLX-PAD cells may be beneficial," CEO Zami Aberman says. (PR)

From other sites
Comments (1)
  • toosmarttofail
    , contributor
    Comments (699) | Send Message
    Buy the warrants (PSTIw) if you like this stock. You'll get 3-5x the upside, with less downside, and it's almost certain this stock will not remain flat.
    6 Jan 2014, 04:12 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs